ONO PHARMACEUTICAL CO has a total of 4,185 patent applications. It decreased the IP activity by 21.0%. Its first patent ever was published in 1962. It filed its patents most often in Japan, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are MARION MERRELL DOW INC, CONCENTRIC ANALGESICS INC and ASAHI KASEI PHARMA CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | Japan | 794 | |
#2 | United States | 587 | |
#3 | EPO (European Patent Office) | 486 | |
#4 | WIPO (World Intellectual Property Organization) | 411 | |
#5 | Canada | 195 | |
#6 | Australia | 133 | |
#7 | China | 132 | |
#8 | Republic of Korea | 130 | |
#9 | South Africa | 120 | |
#10 | Taiwan | 107 | |
#11 | Brazil | 93 | |
#12 | United Kingdom | 90 | |
#13 | Mexico | 88 | |
#14 | Germany | 85 | |
#15 | France | 81 | |
#16 | Israel | 80 | |
#17 | Norway | 79 | |
#18 | Hungary | 75 | |
#19 | New Zealand | 65 | |
#20 | Denmark | 33 | |
#21 | Switzerland | 31 | |
#22 | Singapore | 24 | |
#23 | Philippines | 22 | |
#24 | Poland | 21 | |
#25 | Belgium | 20 | |
#26 | Hong Kong | 20 | |
#27 | Italy | 20 | |
#28 | Netherlands | 20 | |
#29 | Sweden | 19 | |
#30 | Spain | 18 | |
#31 | Ireland | 18 | |
#32 | Argentina | 10 | |
#33 | Czechia | 10 | |
#34 | Finland | 9 | |
#35 | Yugoslavia (Serbia and Montenegro) | 8 | |
#36 | Malaysia | 6 | |
#37 | Morocco | 5 | |
#38 | Slovenia | 5 | |
#39 | Luxembourg | 4 | |
#40 | Peru | 4 | |
#41 | Russian Federation | 4 | |
#42 | Greece | 3 | |
#43 | Portugal | 3 | |
#44 | Dominican Republic | 2 | |
#45 | Ecuador | 2 | |
#46 | India | 2 | |
#47 | Iceland | 2 | |
#48 | Kenya | 2 | |
#49 | Serbia | 2 | |
#50 | Austria | 1 | |
#51 | Cyprus | 1 | |
#52 | Jordan | 1 | |
#53 | Lithuania | 1 | |
#54 | Ukraine | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Machines | |
#5 | Macromolecular chemistry and polymers | |
#6 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Hayashi Masaki | 319 |
#2 | Shibayama Shiro | 271 |
#3 | Arai Yoshinobu | 198 |
#4 | Kobayashi Kaoru | 177 |
#5 | Takaoka Yoshikazu | 142 |
#6 | Nakai Hisao | 140 |
#7 | Tani Kousuke | 125 |
#8 | Takeuchi Jun | 123 |
#9 | Wakatsuka Hirohisa | 120 |
#10 | Maruyama Takayuki | 117 |
Publication | Filing date | Title |
---|---|---|
WO2021080015A1 | Modulators of trek (twik related k+ channels) channel function | |
WO2021080013A1 | Inhibitors of trek (twik related k+ channels) channel function | |
WO2021043245A1 | Hydantoin derivative | |
WO2021033729A1 | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
WO2021025140A1 | Dual-specific protein | |
WO2021025031A1 | Biomarker for accessing efficacy of immune checkpoint inhibitor | |
WO2021020416A1 | Bispecific antibody | |
WO2021010492A1 | Compound having kdm5 inhibitory activity and pharmaceutical use thereof | |
WO2021006199A1 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein | |
WO2020262603A1 | Ep2 antagonist | |
WO2020250940A1 | Immunosuppression agent | |
WO2020116636A1 | Immunosuppressant | |
WO2020111018A1 | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
WO2020059812A1 | Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt | |
JP2020023490A | Pharmaceutical composition including compound having somatostatin receptor actuation activity | |
WO2020027200A1 | Therapeutic agent for cartilage disease | |
WO2020027150A1 | Benzene derivative | |
WO2019240246A1 | Novel salts and novel crystal forms of piperidinol derivatives | |
EP3789040A1 | Preventive and/or therapeutic agent for autoimmune disease comprising compound having btk inhibitory activity as active ingredient | |
US2021087141A1 | Compounds having s1p5 receptor agonistic activity |